Dataset Information


Gene Expression Analysis in Peripheral Blood of Patients with Rheumatoid Arthritis

ABSTRACT: Peripheral blood cells in patients with rheumatoid arthritis before/after IL-6 inhibition The obtained conclusions on the change of each gene expression level before and after MRA medication were as follows. (1) In the case of IL-6, the specific time profile that the expression level dropped at day 21 and increased to some extent at day 42 was observed in 2 of 18 subjects. In other subjects, quite small change or small increase after day 7 was observed. (2) In the case of IL-6R as well as in IL-6, the specific time profile that the expression level dropped at day 21 and increased to some extent at day 42 was observed in 1 of 18 subjects. In other subjects, slow and small increase was observed in 6 of 18. (3) The ratio of mRNA expression level of membrane and soluble type of IL-6R showed marginal difference after tocilizumab treatment, (4) The distinct change of expression level of cytochrome P450 mRNA after tocilizumab treatment was hardly observed in most patients. The measurement of expression level of several genes shown below in peripheral blood of human subjects (18 patients with rheumatic disease) before and after tocilizumab medication using DNA microarray (Hitachi human oligo chip) was conducted in this test, 1) Interleukin 6 (IL-6), membrane IL-6 receptor (IL-6R) and soluble type of the IL-6R, 2) several cytochrome P450 as follows: CYP3A4, CYP2D6, CYP2C9, CYP2C19. Number of human subjects was 18 and peripheral blood samples drawn at 4 time points: day 0 (the first Omeprazole administration was done), day 7 (Tocilizumab administration was done), day 21 and day 42 for each subject were analyzed. On day 0 and day 7, the blood sampling was done before drug administration.

ORGANISM(S): Homo sapiens  

SUBMITTER: Norihiro Nishimoto   Midori Suzaki   Tomomi Tsuru  Kimio Terao  Takahiro Kakehi  TERAO KIMIO 

PROVIDER: E-GEOD-12653 | ArrayExpress | 2010-06-24



altmetric image


Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.

Nishimoto Norihiro N   Terao Kimio K   Mima Toru T   Nakahara Hideko H   Takagi Nobuhiro N   Kakehi Takahiro T  

Blood 20080910 10

Interleukin-6 (IL-6) plays pathologic roles in immune-inflammatory diseases such as rheumatoid arthritis (RA) and Castleman disease. By inhibiting IL-6 receptors (IL-6Rs), tocilizumab (a humanized anti-IL-6R antibody) ameliorates the symptoms of these diseases and normalizes acute-phase proteins, including C-reactive protein (CRP). We found that tocilizumab treatment increased serum levels of IL-6 and soluble IL-6R (sIL-6R). To investigate the pathologic significance of these increases, we analy  ...[more]

Similar Datasets

2009-09-03 | GSE12653 | GEO
2014-09-09 | E-GEOD-61201 | ArrayExpress
2014-08-06 | BIOMD0000000537 | BioModels
2014-08-05 | BIOMD0000000534 | BioModels
2014-08-06 | BIOMD0000000536 | BioModels
2014-08-05 | BIOMD0000000535 | BioModels
| GSE78922 | GEO
2012-12-31 | E-GEOD-34562 | ArrayExpress
2013-12-30 | E-GEOD-45867 | ArrayExpress
| GSE93105 | GEO